Absolute Pharmacy, LLC, Lutz, FL

Is Absolute Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does Absolute Pharmacy, LLC hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH28122 for ABSOLUTE PHARMACY, LLC (dba ABSOLUTE PHARMACY), LUTZ, status Clear and PH28269 for ABSOLUTE PHARMACY, LLC, LUTZ, status Closed. The Texas State Board of Pharmacy also lists nonresident license 32376 for ABSOLUTE PHARMACY LLC, LUTZ, FL, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 1666 for Absolute Pharmacy Llc, Lutz, FL, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6452 for Absolute Pharmacy, LLC, Lutz, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023628 for ABSOLUTE PHARMACY LLC, LUTZ, FL, status ACTIVE and license 054018774 for ABSOLUTE PHARMACY LLC, LUTZ, FL, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002755 for ABSOLUTE PHARMACY LLC, LUTZ, FL, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001475 for ABSOLUTE PHARMACY LLC, LUTZ, FL, status Expired, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301010562 for Absolute Pharmacy LLC, Lutz, FL, status Active, as of Nov 10, 2026.

Has Absolute Pharmacy, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jul 14, 2021) and 1 FMD-145 letter (Jul 14, 2021) for Absolute Pharmacy, LLC. State board actions: no Florida Board of Pharmacy action on licenses PH28122 and PH28269 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 6 actions: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision” dated Nov 8, 2023, case AC 7100 on nonresident license NRP 1666, “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Nov 8, 2023, case AC 7100 on nonresident license NSC 100827 and “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision” dated Nov 8, 2023, case AC 7100 on nonresident license NRP 1666, and more listed below. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Reprimand” dated Sep 17, 2023, case 2021003666 on nonresident license 054018774.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Absolute Pharmacy, LLC
Location
Lutz, FL
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Jul 14, 2021
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 12 observations
State board records
License found: PH28122, Clear; PH28269, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Absolute Pharmacy, LLC, a 503A facility, with 2 dated actions.

Document
Jul 14, 2021Warning letter close-outWarning Letter Close Out Issued 07/14/2021Not linked by FDA
Jul 14, 2021FMD-145 letterFMD-145 Issued 07/14/2021Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Absolute Pharmacy, LLC, Lutz, FL (FEI number 3011116100), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 11, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3011116100966651
Nov 19, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011116100906086

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 12 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Oct 27, 2014 to Nov 19, 2014: 12 observations

Firm on the cover
Absolute Pharmacy, LLC, 16011 N Nebraska Ave suite 1 03, Lutz, FL 33549-6158
FEI number
3011116100
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
DISTRICT I\ODR£SS ANO l'HOI'£ NIJMBCR
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile do not include validation ofthe sterilization process.

Specifically,

A. Your firm’s REDACTED (b)(4) sterilization procedures currently being p erformed for the REDACTED (b)(4) sterilization of all sterile drug products are not validated. This includes lack of REDACTED (b)(4).

U)IGJ.

(b)(4)

B. Your pharmacist stated he does not have a written calibration program and could not provide calibration docwnentation for the following equipment:

1. No documentation could be provided for your REDACTED (b )(4) showing it has been calibrated and appropriately REDACTED (b)(4). 2. The REDACTED (b)(4) used to sterilize finished drug product and compone nts has not been REDACTED (b)(4) during calibration.

(b) (4)

(b) (4)

ttDBJI

Observation 2

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established, written, and followed.

Specifically, the media fills documented as being conducted by your pharmacist within the Buffer room and under the laminar flow hood were found to be deficient in that they do not accurately simulate

current production processes and conditions that represent the most stressful/challenging conditions and optimize detection ofany microbiological contamination. For example, there is no media fill data for your current operation of filling over REDACTED (b)(4) multi-dose glass vials (10 mL) for a prepared b atch th at uses REDACTED (b)(4) glass vials, stoppers, caps that are sterilized in-house.

Observation 3

The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.

Specifically,

A. I could not verify the claimed classifications for these areas based on the inadequate certification documentation that was provided to me during this inspection. For example:

1. No leak test was performed on the HEP A filters inside youi Ante room, Gowning room,

and Buffer room. 2. Air flow measurements were not conducted under dynamic conditions. 3. No dynamic airflow pattern studies (i.e., smoke studies) have been performed in the

laminar flow hood inside your Buffer room.

B. There is no continuous or at least periodically monitoring of air pressure differentials during production from the buffer room and ante room to the surrounding non-classified pharmacy area. Your pharmacist stated that he records a REDACTED (b)(4) value from the magnehelic press ure gauges in the morning, which are located on the outside entrance into the ante room. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions .

Specifically,

A. I could not verify that media used for collecting environmental samples is adequate to detect growth of violative organisms at low levels due to the following:

1. Your pharmacist has not included disinfectant neutralizers (e.g., REDACTED (b)(4)) when preparing in-house REDACTED (b)(4) plates.

(b) ( 4 )

2. Your pharmacist uses REDACTED (b)(4) for growth promotion testing conducted for the media p repared in-house. No documentation could be provided s howing this is an acceptable, consistent control.

B. Personnel monitoring within all classified areas is not adequate based on the following:

1. Fingertip sampling uses the above mentioned inadequate media that is prepared in-house. 2. Your pharmacist's gowning materials have never been sampled after preparation of sterile drug products and his gowning technique has not been qualified.

C. Air and surface sampling within all classified areas is not adequate based on the following:

1. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. Your pharmacist uses non-sterile disinfectants (e.g., REDACTED (b)(4)) to cl ean the laminar flow hood where sterile drug products are prepared.

(b)(4 )

B. No sporicidal agent is used to clean your classified areas, including the laminar flow hood where sterile drug products are prepared.

Observation 6

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, gowning procedures are not being followed as well as gowning qualifications have not been conducted for your pharmacist that compounds sterile drugs in the Buffer room and under the laminar flow hood. For example, I observed inconsistent and inadequate gowning practices during this inspection as described below:

A. There is no demarcation ofthe dirty and clean side ofthe Gowning room entering into the Buffer

room. I observed that the pharmacist walked all over the Gowning room during his gowning.

B. The pharrnacist does not follow your SOP 9.100 "REQUIRED GARB FOR CLEAN ROOM

FACILITY ACCESS", which states a sterile face mask should be worn. Your pharmacist stated he wears a face mask that is non-sterile while preparing sterile drug products. There is no evidence that your firm has purchased any sterile face masks to be used in the preparation of sterile drugs.

C. I observed the pharmacist handling and placing his face mask and goggles on his face prior to washing his hands.

Observation 7

There are no written standards or specifications, methods oftesting, methods of cleaning, methods ofsterilization, and methods ofprocessing to remove pyrogenic properties.

Specifically,

A. The REDACTED (b)(4) has not been validated. This process is used f or all laboratory glassware used in the filling of sterile drug products.

(b)(4 )

B. The REDACTED (b)(4) have not been validated. This pr ocess is used for finished product vials, rubber stoppers and caps used in the filling of sterile drug products.

(b) (4)

C. Glass vials, caps, rubber stoppers, and beakers sterilized and/or depyrogenated in-h ouse, are not identified in a way that would allow a trace back to the REDACTED (b)(4)/batch.

Observation 8

Testing and release ofdrug product for distribution do not include appropriate laboratory determination ofsatisfactory conformance to the final specifications and identity and strength ofeach active ingredient prior to release.

Specifically,

A. Your firm has not validated sterility and endotoxin testing to ensure substances in your product formulations do not interfere with the test.

B. Your firm has never performed testing to determine the preservative (i.e., REDACTED ( b)(4)) content for any of your liquid sterile drug products prior to distribution : vitamin B12, Methionine/Inositol/Choline Chloride (MIC)+vitamin B12 and MIC+vitamin B1+vitamin B12.

b) (4 )

DIJIIII

C. Your firm has never tested the potency or reconstitution time of your steril e REDACTED (b)(4) drug products prior to distribution: Human Chorionic Gonadotropin, Melanota n II Acetate, and Sermorelin+Growth Hormone Releasing Peptide (GHRP)-2+GHRP-6.

Observation 9

Batch production and control records do not include complete infonnation relating to the production and control ofeach batch.

Specifically for the compounding ofsterile drugs at your firm, you could not provide docwnentation stating what steps were completed, when they were completed, and by whom.

Observation 10

Time limits are not established when appropriate for the completion ofeach production phase to assure the quality ofthe drug product.

Specifically, I could not verify hold times or the length of time it took to perform critical steps in the compounding of sterile drugs (e.g., Cyanocobalamin, Human Chorionic Gonadotropin, MIC+B12), suc h REDACTED (b)(4) of the sterile drug products since batch production and co ntrol records were incomplete.

(b)(4)

Observation 11

Each lot ofa component, drug product containers, and closures liable to objectionable microbiological contamination is deficiently subjected to microbiological tests before use.

Specifically,

A. Your firm has no qualified vendor program and no documentation could be provided showing you have qualified any of your bulk drug substance (e.g., REDACTED (b)(4) or component suppliers.

B. Your firm has not verified that any CoA test results are reliable for any incoming bulk drug substance used in the preparation ofsterile drug products.

Observation 12

A. The labels of your outsourcing facility's drug products do not include information required by

section 503B(a)(l0). Specifically,

1. Your firm's labels affixed to the drug products do not contain the date for which the drug was compounded, as required by 503B(a)(lO)(A)(iii)(V); and 2. The statement "Not for resale" is not present on certain drug product labels, as required by section 503B(a)(10)(A)(iii)(IX).

Examples include the following drug product labels: HCG Injection 5,000 USP Units/Vial; Cyanocobalamin USP l,OOOmcg/mL; Sennorelin/GHRP-2/GHRP-6 10mg/3mg/3mg Vial; MIC +812 25/50/SOmg/mL + 20mcg/mL; and Melatonin II Acetate lOmg/Vial.

B. The containers from which the individual units ofthe drug are removed for dispensing or for

administration do not adequately display the phone number to facilitate adverse event reporting (1-800-FDA-1 088), nor does it display www.fda.gov/medwatch} as required by section 503B(a)(l O)(B)(ii).

ll/ 19/2014(Wed)

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH28122PharmacyABSOLUTE PHARMACY, LLC (dba ABSOLUTE PHARMACY)LUTZClear
PH28269PharmacyABSOLUTE PHARMACY, LLCLUTZClosed

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
32376Non-Resident (Not Located in Texas)ABSOLUTE PHARMACY LLCLUTZ, FLActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NRP 1666Non Resident PharmacyAbsolute Pharmacy LlcLutz, FLActive

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6452OSPAbsolute Pharmacy, LLCLutz, FLActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054023628LICENSED PHARMACYABSOLUTE PHARMACY LLCLUTZ, FLACTIVE
054018774LICENSED PHARMACYABSOLUTE PHARMACY LLCLUTZ, FLCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002755NONRESIDENT PHARMACYABSOLUTE PHARMACY LLCLUTZ, FLACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001475Non Resident PharmacyABSOLUTE PHARMACY LLCLUTZ, FLExpired

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301010562PharmacyAbsolute Pharmacy LLCLutz, FLActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.